<DOC>
	<DOC>NCT00767494</DOC>
	<brief_summary>The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs. AZOPT dosed BID in patients with open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>18 YOA or older Either gender or any race OAG or OHT Currently on stable (at least 4 weeks) IOP lowering medication IOP at screening visit â‰¥ 18mmHg in at least one eye Mean IOP in same eye (at both eligibility 1&amp;2 visits 24 and 36 mmHg at 9AM 21 and 36 mmHg at 11AM and 4PM Able to discontinue use of IOP lowering medication for a minimum wash out period of 5 to 28 days prior to eligibility visit 1 Related to disease condition being investigated (OAG or OHT) in either eye Severe central visual field loss Angle shaffer grade &lt; 2 C/D ratio &gt;0.8(horizontal or vertical measurement) Related to ocular patient history or current ocular condition in either eye BSCVA worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal) Ocular infection or inflammation or laser surgery within the last 3 months Intraocular surgery or trauma with the last 6 months Any abnormality preventing reliable applanation tonometry History or chronic, recurrently or current severe inflammatory disease History of or current clinically significant or progressive retinal disease History of or current ocular pathology(including severe dry eye) that would affect the conduct of the study Related to systemic or ocular medication in either eye Allergy/hypersensitivity to study medications Unable to discontinue glucocorticoid at least 4 weeks prior to the study or unable to remain off these medications during the study period Use of oral CAIs during the study Recent use (&lt;4 weeks prior to the study) of Aspirin (&gt;1 gram) Less than 30 days stable dosing regimen of medications used on a chronic basis that may affect IOP Therapy with another investigational agent within 30 days prior to the Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>OAG</keyword>
	<keyword>OH</keyword>
	<keyword>Open-angle glaucoma or ocular hypertension</keyword>
</DOC>